Company / Operating Cash Flow
Compass Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$44.9M
FY2024
5-year range
-$44.9M / -$19.7M
FY2020-FY2024
Trend
-10.4%
vs FY2023
Sector context
#91 of 214
Health Care
What the data says
At -$45M, Compass Therapeutics, Inc.'s operating cash flow ranks #91 of 214 in the Health Care sector. Operating Cash Flow has declined for 3 consecutive years, from -$20M in FY2021 to -$45M in FY2024.
Based on SEC 10-K filings.
-$45M in FY2024.
Declined from -$34M to -$45M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#91 of 214 in Health CareTop 43% of 214This company -$44.9M Sector average $663.6M
▼
-106.8% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2024, operating cash flow decreased 10.4% year-over-year.
- Ranks #91 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$44.9M | -10.4% |
| FY2023 | -$40.6M | -19.0% |
| FY2022 | -$34.1M | -73.5% |
| FY2021 | -$19.7M | +26.6% |
| FY2020 | -$26.8M | +15.6% |
| FY2019 | -$31.7M | -96792.5% |
| FY2018 | -$32.8K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026